KR950016757A - Drug addiction therapeutic composition - Google Patents

Drug addiction therapeutic composition Download PDF

Info

Publication number
KR950016757A
KR950016757A KR1019930030436A KR930030436A KR950016757A KR 950016757 A KR950016757 A KR 950016757A KR 1019930030436 A KR1019930030436 A KR 1019930030436A KR 930030436 A KR930030436 A KR 930030436A KR 950016757 A KR950016757 A KR 950016757A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
therapeutic composition
present
acid
Prior art date
Application number
KR1019930030436A
Other languages
Korean (ko)
Other versions
KR0129799B1 (en
Inventor
염제호
김영만
유영효
박명환
정종근
원종엽
Original Assignee
이승철
주식회사 대웅제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이승철, 주식회사 대웅제약 filed Critical 이승철
Priority to KR1019930030436A priority Critical patent/KR0129799B1/en
Publication of KR950016757A publication Critical patent/KR950016757A/en
Application granted granted Critical
Publication of KR0129799B1 publication Critical patent/KR0129799B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 타우로우루소데옥시콜린산을 함유함을 그 특징으로 하는 약물중독의 치료용 의약조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the treatment of drug poisoning, characterized in that it contains tauurosodeoxycholine acid.

본 발명의 바람직한 의약조성물은 타우로우루소데옥시콜린산 25 내지 1000mg을 함유하며, 추가로 적어도 하나의 약제학적으로 허용되는 담체를 함유할 수 있다.Preferred pharmaceutical compositions of the present invention contain from 25 to 1000 mg of taurousodeoxycholine acid, and may further contain at least one pharmaceutically acceptable carrier.

특히 본 발명의 의약조성물은 약물중독의 치료에 효과가 있는 약제로서 독성이 없고, 제제학적으로 안정성이 양호하여 산업적으로 매우 유용한 발명이다.In particular, the pharmaceutical composition of the present invention is a drug which is effective in the treatment of drug poisoning, is non-toxic, and has good pharmaceutical stability and is an industrially useful invention.

Description

약물중독 치료제 조성물Drug addiction therapeutic composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (7)

타우로우루소데옥시콜린산을 함유함을 특징으로 하는 약물중독의 치료용 의약조성물.A pharmaceutical composition for the treatment of drug poisoning, characterized by containing taurorusodeoxycholine acid. 제1항에 있어서, 경구투여용 단위제제로 제형화된 의약조성물.The pharmaceutical composition according to claim 1, formulated as a unit dosage form for oral administration. 제2항에 있어서, 제제가 정제, 캅셀제, 연질캅셀제 액제로함을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 2, wherein the preparation is a tablet, a capsule, or a soft capsule solution. 제2항에 있어서, 단위제제당 타우로우루소데옥시콜린산을 25 내지 1000mg함유함을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 2, which contains 25 to 1000 mg of taurousodeoxycholine acid per unit formulation. 제4항에 있어서, 단위제제당 타우로우루소데옥시콜린산을 25 내지 500mg함유함을 특징으로 하는 의약조성물.The pharmaceutical composition according to claim 4, which contains 25 to 500 mg of taurousodeoxycholine acid per unit formulation. 제1항 내지 5항중 어느 하나에 있어서, 추가로 적어도 하나의 약제학적으로 허용되는 담체를 함유하는 의약조성물.The pharmaceutical composition according to any one of claims 1 to 5, further comprising at least one pharmaceutically acceptable carrier. 제6항에 있어서, 담체가 회석제, 활택제, 결합제, 붕해제 또는 안정화제로 부터 선택된 1종 이상의 성분인 의약조성물.The pharmaceutical composition according to claim 6, wherein the carrier is at least one component selected from a diluent, a lubricant, a binder, a disintegrant or a stabilizer. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930030436A 1993-12-28 1993-12-28 Compositions for treatment of drug intoxication KR0129799B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019930030436A KR0129799B1 (en) 1993-12-28 1993-12-28 Compositions for treatment of drug intoxication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930030436A KR0129799B1 (en) 1993-12-28 1993-12-28 Compositions for treatment of drug intoxication

Publications (2)

Publication Number Publication Date
KR950016757A true KR950016757A (en) 1995-07-20
KR0129799B1 KR0129799B1 (en) 1998-04-09

Family

ID=19373433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930030436A KR0129799B1 (en) 1993-12-28 1993-12-28 Compositions for treatment of drug intoxication

Country Status (1)

Country Link
KR (1) KR0129799B1 (en)

Also Published As

Publication number Publication date
KR0129799B1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
KR950031069A (en) How to suppress bone loss and lower serum cholesterol
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
KR950007841A (en) Sustained-release drug formulations containing tramadol salts
KR880011199A (en) Novel peptide compounds, methods for their preparation and pharmaceutical compositions containing them
ATE113604T1 (en) MOMETASONE FUROATE MONOHYDRATE, PROCESS FOR ITS PREPARATION AND THE CONTAINING PHARMACEUTICAL COMPOSITIONS.
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
SE9901573D0 (en) New compounds
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
NO304113B1 (en) Crystalline thiagabine hydrochloride monohydrate, pharmaceutical composition comprising it, and use thereof for the manufacture of a medicament
HUP0301390A2 (en) Oral pharmaceutical composition containing valsartan
KR880007074A (en) medicine
CA2466770A1 (en) Liquid pharmaceutical formulations of acetaminophen and an alkali metal 1-lactate salt
WO2000066550A8 (en) New compounds
FR2500303B1 (en)
KR890004705A (en) Antiviral agents
KR960703593A (en) Inhibition of Smooth Muscle Cell Migration by (R) -Amlodipine
KR950016757A (en) Drug addiction therapeutic composition
KR950016756A (en) Fatigue Recovery Composition
KR950016755A (en) Pharmaceutical composition for the prevention and treatment of hepatitis
KR980002033A (en) Triazole derivatives or salts thereof
MY133508A (en) Polymorphs of a crystalline azobicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
KR920703067A (en) L-α-glycerophoryl-D-myo-inositol for the treatment of peripheral neurological and brain diseases
CA2409845A1 (en) Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
KR950700063A (en) Brofaromine as an agent for treating post-traumatic stress

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120328

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20130327

Year of fee payment: 17

EXPY Expiration of term